For people with heart disease: Although L-carnitine supports the cardiovascular system, serious conditions require consultation with a doctor
These controversial findings might be related to differences in tissues or species, and further studies need to determine the underlying mechanisms involved
However, as with many medications, there are potential side effects
In the U.S., 29% of adults meet conditions for an AUD diagnosis over their lifetime and an estimated 11% in the most recent year
The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases
On March 2, 2023 and June 16, 2023 Lexaria announced that in pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: Lowered blood glucose levels by 19.9% (p0.05) Lowered overall body weight by 7% sustained over 8 weeks Increased locomotor activity (p0.05) Lowered triglyceride levels by more than 25% (p0.007) Lowered blood urea nitrogen levels by 27.9% (p0.001) On August 2, 2023 Lexaria announced its intention to study weight loss and diabetes control in a human population using DehydraTECH-CBD
